Eli Lilly and Company
Key numbers
What the whole company is worth on the stock market.
Price ÷ last year's profit per share. Higher means investors pay more for each $1 of profit.
The same ratio using next year's expected profit.
How much the stock swings compared with the market: 1 moves like the market, 1.5 moves 50% more.
Yearly dividend as a share of the price.
What analysts say
30 analysts
Recent analyst actions
Financial health
Nine checks of profitability, debt and efficiency. 7–9 strong, 4–6 average, 0–3 weak.
Profitability and debt
Short-term assets ÷ short-term debts. Below 1 means more due within a year than on hand.
Compared with similar companies
The company next to its sector peers.
| Company | Price | P/E | P/B | Market value |
|---|---|---|---|---|
| LLYEli Lilly and Company | 1,179.27 | 41.6 | 38.3 | $1.11T |
| JNJJohnson & Johnson | 261.44 | 29.9 | 6.1 | $630.04B |
| ABBVAbbVie Inc. | 276.47 | 77.4 | 94.4 | $488.55B |
| MRKMerck & Company, Inc. | 145.60 | 113.2 | 5.0 | $359.22B |
| UNHUnitedHealth Group Incorporated | 379.30 | 24.1 | 3.2 | $340.46B |
| TMOThermo Fisher Scientific Inc | 658.02 | 34.9 | 4.1 | $243.30B |
| AMGNAmgen Inc. | 414.87 | 25.7 | 20.4 | $224.29B |
| ABTAbbott Laboratories | 99.60 | 31.8 | 4.2 | $172.35B |
| PFEPfizer, Inc. | 28.28 | 37.2 | 1.6 | $161.19B |
| BMYBristol-Myers Squibb Company | 59.12 | 13.0 | 5.9 | $120.77B |
| Sector average | 42.9 | 18.3 |
About the company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for c…
Data: Elcaro Core (Yahoo Finance, Binance, Treasury) · Information, not investment advice.